Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Evaluation of memantine for neuroprotection in dementia
Autore:
Jain, KK;
Indirizzi:
Jain PharmaBiotech, CH-4057 Basel, Switzerland Jain PharmaBiotech Basel Switzerland CH-4057 CH-4057 Basel, Switzerland
Titolo Testata:
EXPERT OPINION ON INVESTIGATIONAL DRUGS
fascicolo: 6, volume: 9, anno: 2000,
pagine: 1397 - 1406
SICI:
1354-3784(200006)9:6<1397:EOMFNI>2.0.ZU;2-P
Fonte:
ISI
Lingua:
ENG
Soggetto:
NMDA RECEPTOR ANTAGONIST; LONG-TERM POTENTIATION; RAT; NEURONS; AMANTADINE; IMPAIRMENT; ISCHEMIA; CHANNELS; CORTEX;
Keywords:
Alzheimer's disease; dementia; excitotoxicity; glutamate; Huntington's disease; HIV-1 dementia; ion channels; memantine; neuroprotection; neurodegenerative disorders; NMDA receptor blockers; Pick's disease; vascular dementia;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
35
Recensione:
Indirizzi per estratti:
Indirizzo: Jain, KK Jain PharmaBiotech, Blasiring 7, CH-4057 Basel, Switzerland Jain PharmaBiotech Blasiring 7 Basel Switzerland CH-4057 zerland
Citazione:
K.K. Jain, "Evaluation of memantine for neuroprotection in dementia", EXPERT OP I, 9(6), 2000, pp. 1397-1406

Abstract

Memantine, a non-competitive NMDA antagonist, has been approved for use inthe treatment of dementia in Germany for over ten years. The rationale foruse is excitotoxicity as a pathomechanism of neurodegenerative disorders. Memantine acts as a neuroprotective agent against this pathomechanism, which is also implicated in vascular dementia. HIV-1 proteins Tar and gp120 have been implicated in the pathogenesis of dementia associated with HIV infection and the neurotoxicity caused by HIV-1 proteins can be blocked completely by memantine. Memantine has been investigated extensively in animal studies and following this, its efficacy and safety has been established and confirmed by clinical experience in humans. It exhibits none of the undesirable effects associated with competitive NMDA antagonists such as dizocilpine. The efficacy of memantine in a variety of dementias has been shown in clinical trials. Memantine is considered to be a promising neuroprotective drug for the treatment of dementias, particularly Alzheimer's disease for which there is no neuroprotective therapy available currently. It can be combined with acetylcholinesterase inhibitors which are the mainstay of current symptomatic treatment of Alzheimer's disease. Memantine has a therapeutic potential in numerous CNS disorders besides dementias which include stroke, CNS trauma, Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), epilepsy, drug dependence and chronic pain. If memantine is approved by the FDA for some of these indications by the year 2005, it can become a blockbuster drug by crossing the US$1 billion mark in annual sales.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 19/01/20 alle ore 20:04:56